Relationship between Patient Characteristics and the Timing of Provision of Explanation about DNAR to Patients with Advanced Lung Cancer.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
01 Dec 2020
Historique:
pubmed: 8 8 2020
medline: 7 4 2021
entrez: 8 8 2020
Statut: ppublish

Résumé

Objective The aim of the present study was to analyze the relationship between the patient characteristics and the timing of provision of an explanation about "Do Not Attempt Resuscitation (DNAR)" by attending physicians to advanced lung cancer patients. Methods We conducted a retrospective analysis of patients with advanced or postoperative recurrent lung cancer in whom systemic therapy was initiated between 2015 and 2016. Results The data of a total of 74 patients with lung cancer, including 59 patients with non-small cell lung cancer and 15 with small cell lung cancer were analyzed. The median overall survival of the patients was 10.0 months. Records of the explanation about DNAR by the physicians were available for 57 of the 74 (77.0%) patients. For 48 (64.9%) patients, the explanation was provided after the discontinuation of anticancer treatment, and for 9 (12.2%) patients, it was provided during the course of anticancer treatment. The provision of an explanation about DNAR during the course of treatment was associated with a poor performance status at the start of treatment (p=0.028), the tumor histology (p=0.037), the presence of driver gene mutation in the tumor (p=0.029), and shorter survival after the discontinuation of anticancer treatment (p<0.001). Conclusion The results suggested that the timing of provision of an explanation about DNAR was associated with patient characteristics and the predicted prognosis.

Identifiants

pubmed: 32759584
doi: 10.2169/internalmedicine.4704-20
pmc: PMC7759716
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2989-2994

Références

Jpn J Clin Oncol. 2015 Mar;45(3):261-6
pubmed: 25480983
JAMA Intern Med. 2014 Apr;174(4):620-4
pubmed: 24493203
Del Med J. 2012 Apr;84(4):117-21
pubmed: 22856102
Tidsskr Nor Laegeforen. 2013 Feb 19;133(4):417-21
pubmed: 23423208
Med Oncol. 2014 Sep;31(9):154
pubmed: 25108600
J Pain Symptom Manage. 2017 May;53(5):821-832.e1
pubmed: 28062339
J Clin Oncol. 2012 Feb 1;30(4):394-400
pubmed: 22203758
Cancer. 2001 Oct 1;92(7):1905-12
pubmed: 11745264
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Support Care Cancer. 1999 May;7(3):128-33
pubmed: 10335930
N Engl J Med. 2010 Apr 1;362(13):1211-8
pubmed: 20357283

Auteurs

Minehiko Inomata (M)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Takahiro Hirai (T)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Naoki Takata (N)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Nozomu Murayama (N)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Kana Hayashi (K)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Zenta Seto (Z)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Kotaro Tokui (K)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Seisuke Okazawa (S)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Kenta Kambara (K)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Shingo Imanishi (S)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Toshiro Miwa (T)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Shoko Matsui (S)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Ryuji Hayashi (R)

Department of Medical Oncology, Toyama University Hospital, Japan.

Kazuyuki Tobe (K)

First Department of Internal Medicine, Toyama University Hospital, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH